A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism
Tóm tắt
Background and aims: Neuromuscular symptoms are frequent features of primary hyperparathyroidism in elderly patients. Whether these symptoms are related to concomitant disorders or to hypercalcemia is of major importance in selecting patients who could benefit by parathyroidectomy. To address this hypothesis, we investigated the effects of transient normalization of calcemia on functional capacity by the administration of a single infusion of the bone resorption inhibitors pamidronate or clodronate. Methods: Functional capacity was evaluated by the functional independence measure (FIM) in 25 patients aged 87.1±0.8 years (means±SEM) with primary hyperparathyroidism. Nine patients aged 88.4±1.1 with primary hyperparathyroidism, not receiving any bisphosphonate, were used as controls. Results: By inhibiting bone resorption, bisphosphonate administration caused transient normalization of calcemia, associated with improved FIM, at a significantly higher level than in untreated patients (+16.1±6.0 vs +4.2±3.2%, p<0.05). Conclusions: If confirmed in a randomized prospective study, these results indicate that a single bisphosphonate infusion, with consecutive transient improvement of functional capacity in relation to plasma calcium normalization, could help in identifying elderly patients who would benefit by parathyroidectomy.
Tài liệu tham khảo
Mallette LE. Review: primary hyperparathyroidism and update: incidence, etiology, diagnosis, and treatment. Am J Med Sci 1987; 293: 239–49.
Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 2036–40.
Bilezikian JP. Primary hyperparathyroidism. In Favus MJ, Ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Philadelphia: Lippincott Williams & Wilkins, 1999: 187–92.
Kristoffersson A, Bostrom A, Soderberg T. Muscle strength is improved after parathyroidectomy in patients with primary hyperparathyroidism. Br J Surg 1992; 79: 165–8.
Chou FF, Sheen-Chen SM, Leong CP. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. Surgery 1995; 117: 18–25.
Colliander EB, Strigard K, Westblad P, Rolf C, Nordenstrom J. Muscle strength and endurance after surgery for primary hyperparathyroidism. Eur J Surg 1998; 164: 489–94.
Deutch SR, Jensen MB, Christiansen PM, Hessov I. Muscular performance and fatigue in primary hyperparathyroidism. World J Surg 2000; 24: 102–7.
Joborn C, Hetta J, Lind L, Rastad J, Akerstrom G, Ljunghall S. Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with long-standing mild hypercalcemia. Surgery 1989; 105: 72–8.
Okamoto T, Gerstein HC, Obara T. Psychiatric symptoms, bone density and non-specific symptoms in patients with mild hypercalcemia due to primary hyperparathyroidism: a systematic overview of the literature. Endocr J 1997; 44: 367–74.
Kochersberger G, Buckley NJ, Leight GS, et al. What is the clinical significance of bone loss in primary hyperparathyroidism? Arch Intern Med 1987; 147: 1951–3.
Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O’Fallon WM, Riggs BI. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999; 14: 1700–7.
Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341: 1249–55.
Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4: 283–91.
Bijvoet OL, Morgan DB, Fourman P. The assessment of phosphate reabsorption. Clin Chim Acta 1969; 26: 15–24.
Buchs B, Rizzoli R, Bonjour JP. Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia. Bone 1991; 12: 47–56.
Minaire P. La mesure d’indépendance fonctionnelle (M.I.F). Historique, présentation, perspectives. Journal de la Réadaptation Médicale 1991; 11: 168–74.
Granger CV, Hamilton BB, Linacre JM, Heinemann AW, Wright BD. Performance profiles of the functional independence measure. Am J Phys Med Rehabil 1993; 72: 84–9.
Ottenbacher KJ, Mann WC, Granger CV, Tomita M, Hurren D, Charvat B. Inter-rater agreement and stability of functional assessment in the community-based elderly. Arch Phys Med Rehabil 1994; 75: 1297–301.
Pollak N, Rheault W, Stoecker JL. Reliability and validity of the FIM for persons aged 80 years and above from a multilevel continuing care retirement community. Arch Phys Med Rehabil 1996; 77: 1056–61.
Stineman MG, Shea JA, Jette A, et al. The Functional Independence Measure: tests of scaling assumptions, structure, and reliability across 20 diverse impairment categories. Arch Phys Med Rehabil 1996; 77: 1101–8.
Inabnet WB, Fulla Y, Richard B, Bonnichon P, Icard P, Chapuis Y. Unilateral neck exploration under local anesthesia: the approach of choice for asymptomatic primary hyperparathyroidism. Surgery 1999; 126: 1004–9.
Schwarz P, Sorensen HA, Momsen G, McNair P, Transbol I. Normal pattern of parathyroid response to blood calcium lowering in primary hyperparathyroidism: a citrate clamp study. Clin Endocrinol (Oxf) 1992; 37: 344–8.
Adami S, Mian M, Bertoldo F, et al. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment. Clin Endocrinol (Oxf) 1990; 33: 391–7.
Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and ild primary hyperparathyroidism. J Bone Miner Res 2001; 16: 113–9.
Marcus R. Diagnosis and treatment of hyperparathyroidism. Rev Endocr Metab Disord 2000; 1: 247–52.